Although intravitreal injection of anti-VEGF drugs has been established to be the first line treatment of CNV in AMD, pathological myopia, and macular edema, in DR and retinal vein occlusion, the anti-VEGF treatment is still invasive. The gene discussed is VEGFA; the disease is myopia.